Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.
Ronald Innerfield

Dr. Ronald Innerfield MD

Vice President of Clinical Affairs, Evidence Based Medicine, Inc.

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Ronald Innerfield, MD, FACE, is Chief of Clinical Trials and Epidemiology, Emeritus, at the Dorothy Bullock Memorial National Diabetes Center. He is also Vice President of Clinical Affairs of Evidence Based Medicine, a site management organization (SMO) in Princeton. Dr. Innerfield was a primary medical reviewer at the Division of Metabolic and Endocrine Drug Products (HFD-410) at CDER/FDA and Associate Director of Medical Research in the Metabolic/GI Division of Bayer, Inc., and Senior Medical Director at PharmaNet, LLC, a leading CRO. He also maintains an active clinical practice in New York's Hudson River Valley. Dr. Innerfield is well recognized in the field of diabetes, on the editorial board of Cardiovascular Diabetology, and has authored several book chapters and peer-reviewed journal articles. He is also a member of several of professional societies, including EASD, The Endocrine Society, the ADA, AMA, and AACE. (This is me - Update Profile)


Employment History

2005 - Unspecified
Vice President of Clinical Affairs, Evidence Based Medicine, Inc.
1994 - Unspecified
Chief of Clinical Trials and Epidemiology , The Dorothy Bullock Memorial National Diabetes Center
1990 - 1994
Medical Officer, FOOD & DRUG ADMINISTRATION
1990 - Unspecified
Physician, Diabetes & Metabolism, PC

GLG NewsSM Analyses by Ronald Innerfield(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Metanalyses, Metapsychoses

September 30, 2009

Controls to blood sugar 'cuts stroke risk' | www.barchester.com

There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore, a marker for increased mortality but not a modifiable risk factor thereofThis is why FDA has mandated cardiovascular safety for new antidiabetic agentsData dredging persists, however

Leading institutions connect with Ronald Innerfield through GLG

GLG Live Meetings with Ronald Innerfield(?)

Recent Seminars

May 22, 2008 | Boston

GLG Seminar: Diabetes and Obesity

June 20, 2007 | Chicago

GLGi: Diabetes and Obesity

June 19, 2007 | New York

GLGi: Diabetes and Obesity Grand Rounds